Transfer from: ammonia-based observation

The success of a new drum often comes from the input of the pharmacist business and a long waiting period. However, more pharmacists have chosen to stay at maturity points, and only a few pharmacists are willing to venture to try to conquer those more difficult.

HER3 points are more difficult. HER3 was pilled several years ago with Minster Point EGFR, HER2 and the HER family, while HER3 was delayed due to low combinations and extremely low inner enzymatic activity.

From the 1989 HER3 point of embarkation to the present, over a period of 30 years, many major pharmacists, including Rod, An, First Three, turned down.

While life-threatening failures have deterred many people, innovative drug research and development is still in the process of insisting on the development of the HER3 node.

As the role of R&D personnel in HER3 is more profound, the convergence of ADC and dual resistance technologies are gradually mature, plunging into dark-sighted HER3 drugs once again today.

Of course, how far do HER3 go from becoming a pill? Can the imaginative space of HER3 not be as large as that of HER2 and EGFR if drugs are available?

These issues are tentative, but it is certain that over the past three decades a very smart group of researchers has paid their own time, casing their own pride and exploring this potential together. They have been insisting, so today, more than yesterday, tomorrow, than today, the distance between HER3 and pills.

/ 01

There are also spectacular births.

The human development factor is a small family with four members - HER1, HER2, HER3 and HER4. As a cross-diaprotein, they can combine cell surfaces with growth causes, carry out signal missions, regulate cell growth, division and rehabilitation, and are associated with the development of many cancers.

In the history of human cancer, a large number of studies have followed clinical trials, suggesting that HER2 is more curative than other poles, such as a single-counter-to-people resistance, and that EGFR is also a critical point in the field of non-small cell lung cancer (NSCLC).

As a member of the HER family, HER3 appears to be somewhat silent in contrast to these two stars.

Compared to other members, HER3 can be described as a “strange” family, with a very weak in-cell ammonia enzymatic activity, 1,000 times less than a fully fought EGFR enzyme.

It is due to the extremely low activity of the HER3 Ammonia Structural Acid, which has led R&D personnel to consider that HER3 is entirely dependent on the activity of its family members, and that HER3 does not have a very important function in itself. Thus, in cancer treatment, HER3 has been neglected for a long time.

However, with the depth of the study, scientists find this invisible HER3 as a “treason”. Two systematic analyses of multi-entities have shown that the HER3 expression is relevant to the overall life cycle. Compared to the HER3 vagina, the death risk of the person expressing HER3 is 1.6 times higher.

In fact, although HER3 was not carcinogenic when expressed separately compared with other family members, when HER3 was integrated with the nervous protein (NRG) formulation, it formed an alternative source fusion with other RTK (acidated ammonia).

In particular, when HER3 came to the head of the two brothers HER2, the mutagenic formation of HER 2: HER3 sources led to the activation of P3K/AKT and MEK/MAPK signal circuits, the promotion of the division, breeding and separation of cells and the survival and development of cancer cells.

As a result, blocking the combination of HER3 points with NRG, or discouraging HER2 from forming a source fusion with HER3, can in theory inhibit the development of cancer.

More importantly, HER3 has proved to be relevant to EGFR, HER2 therapy.

It has been considered that the formation of a three-potential fusion between HER2, HER3, IGF1R is the main inducive agent that drives single resistance from breast cancer cells. After the research was carried out with HER3, cancer cells were receptive to a single resistance. In addition, NRG1 stimulation can also be used in HER2 to induced single-resistant drugs in breast cancer cells.

In the case of EGFR resistance, a wide range of disturbances and signals were observed in the HER family, i.e., the interruption of a signal sent by a body and the possibility of compensation in the other. This is why it is a possible method of breaking the EGFR resistance to many HER family sites, including HER3.

HER3 is likely to be a key to breaking EGFR and HER2 resistance. Given the widespread occurrence of HER2 and EGFR resistance, if HER3 is able to address this drug-resistant problem, it will meet the enormous clinical unmet need. In this context, the development of HER3 drugs is necessary, and the “prevenous” is also a spring.

/

Emerging savers

Since HER3 is extremely low in its enzymatic activity, it is not possible to be made a small molecular enzyme inhibitor, which alone becomes the starting point for HER3 research and development.

Several sections of HER3, including U3-1287 and R$5479599 in RupD, stand alone in clinical trials. Unfortunately, research and development around HER3 has largely failed. Clinical tests found that these HER3 are generally ineffective.

The development of HER3 drugs has also resulted in a cooling period. As ADC, dual resistance technologies mature, HER3’s drug development is in the second spring.

At present, the most promising success of HER3 can be found in ADC drugs. Because of the resistance of HER3 to block NRG formulations by combining HER3, low HER3 combinations may affect the efficacy of medicines. In contrast, ADC’s advantage is that cancer cell deaths are caused by inducement to internal annexation and degradation, without relying entirely on HER3 to induce cancer cell deaths.

There are now two sections of HER3 ADC in the clinical phase, one of which is U3-104 in total.